Story perspectives

Over 200 lawsuits claim GLP-1 drugs cause NAION

By Drooid · Sep 23, 2026, 12:05 AM UTC · How we work

Summary

Patients Sue GLP-1 Makers

U.S. patients have filed more than 200 lawsuits against Novo Nordisk and Eli Lilly, alleging GLP-1 drugs cause NAION.
The suits target Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity.
European regulators deem semaglutide-related NAION a very rare side effect, up to one in 10,000 cases.
Novo Nordisk calls the suits meritless, while Eli Lilly says evidence is insufficient.

Summary

Arizona Medicaid Bars Ozempic

Novo Nordisk and Eli Lilly launched oral GLP-1 obesity treatments in the U.S. in 2026, intensifying competition.
Ozempic costs over $1,300 in the U.S. but as little as $215 in Mexican pharmacies.
Arizona Medicaid excludes Ozempic unless patients have diabetes, heart failure, hypertension, or related diagnoses.
Novo Nordisk reported $9.943 billion global sales for Mounjaro in Q2 2026, part of $27.693 billion six-month total.

1 of 2

Patients Sue GLP-1 Makers

U.S. patients have filed more than 200 lawsuits against Novo Nordisk and Eli Lilly, alleging GLP-1 drugs cause NAION.
The suits target Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity.
European regulators deem semaglutide-related NAION a very rare side effect, up to one in 10,000 cases.
Novo Nordisk calls the suits meritless, while Eli Lilly says evidence is insufficient.

1 / 2